A Novel Multi-gene Marker Blood Test To Increase Community Participation In Colorectal Cancer Screening.
Funder
National Health and Medical Research Council
Funding Amount
$581,116.00
Summary
Bowel cancer screening programs are vital for early detection and prevention, but participation with the traditional faecal testing mode is less than 35%. Reasons include dislike or unsuitability for faecal testing. These barriers could be overcome and participation could increase using a different sampling mode for the screening test. We have developed a blood test for bowel cancer and will investigate if people who will not screen with the stool test will screen with the blood test instead.
Population Based Genetic Testing For High-risk Breast And Ovarian Cancer Predisposition Genes
Funder
National Health and Medical Research Council
Funding Amount
$1,112,985.00
Summary
Inherited mutations in BRCA1 and BRCA2 confer a very high risk of breast and ovarian cancer. Importantly, once carriers are identified, effective strategies are available that can dramatically reduce the risk of cancer. We will perform genetic testing of a healthy western population to identify breast/ovarian cancer genes before the women develop cancer. Population-based screening could significantly reduce the incidence of these diseases.
Identification And Characterisation Of Novel FLT3-ITD Co-operating Mutations
Funder
National Health and Medical Research Council
Funding Amount
$659,245.00
Summary
Acute myeloid leukaemia is a cancer of the blood and bone marrow. We have identified new genes that act with the known oncogene FLT3-ITD in myeloid disease. We will examine in detail how these new genes contribute to the development of AML. This will aid in the development of new therapies for groups of AML patients with these mutations.
AusGo-SHEMO….Let’s Go! Australian Gold Standard Health Economics Model Of Osteoporosis
Funder
National Health and Medical Research Council
Funding Amount
$378,959.00
Summary
We will develop an unbiased, gold standard, validated, transparent health economics model of osteoporosis to identify cost-effective screening and treatment strategies, and that will be made widely available to all stakeholders. Without this model, scarce health care resources may be squandered on osteoporosis screening strategies and osteoporosis-related fracture prevention medications that are not cost-effective. Worse, patient access to cost-effective medications may be delayed.
Optimising Men’s Uptake Of FIT Screening For Bowel Cancer: A Population Based Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$552,522.00
Summary
Men are more likely to die from bowel cancer but are not participating in the National Bowel Cancer Screening program to the same extent as women. The research group has devised simple messages that their previous research shows encourages men to use the screening kit. The team will compare the use of kits among men who get the Government’s usual invitations, with a group who receive invitations with the messages for men.
Circulating Tumour DNA (ctDNA) As A Diagnostic Tool In Colorectal Cancer: Role In Screening And Early Detection Of Metastatic Or Recurrent Disease
Funder
National Health and Medical Research Council
Funding Amount
$500,478.00
Summary
These studies will be exploring the value of using a blood test to detect cancer DNA as a screening test for colorectal cancer. This test promises to be superior to faecal blood testing, which is currently performed as part of the National Bowel Cancer Screening Program. It may also have advantages over colonoscopy as a screening tool. Given the likely acceptability of having a blood based screening test, it is expected that participation rates in bowel cancer screening, which has been shown to ....These studies will be exploring the value of using a blood test to detect cancer DNA as a screening test for colorectal cancer. This test promises to be superior to faecal blood testing, which is currently performed as part of the National Bowel Cancer Screening Program. It may also have advantages over colonoscopy as a screening tool. Given the likely acceptability of having a blood based screening test, it is expected that participation rates in bowel cancer screening, which has been shown to save lives, will be greatly increased.Read moreRead less
Non-invasive Retinal Vein Pulsation Pressure Measurement: A New Assessment Of Glaucoma Treatment.
Funder
National Health and Medical Research Council
Funding Amount
$557,666.00
Summary
Glaucoma is the second most common cause of blindness. It is a slowly degenerating disease and the level of treatment required is difficult to predict. At present there is no way of knowing whether the eye is receiving inadequate treatment. We have shown that retinal vein pulsation pressure measurements are an indicator of the likelihood of glaucoma progression. Our proposed studies hope to demonstrate for the first time that it is feasible to determine the appropriate treatment level for indivi ....Glaucoma is the second most common cause of blindness. It is a slowly degenerating disease and the level of treatment required is difficult to predict. At present there is no way of knowing whether the eye is receiving inadequate treatment. We have shown that retinal vein pulsation pressure measurements are an indicator of the likelihood of glaucoma progression. Our proposed studies hope to demonstrate for the first time that it is feasible to determine the appropriate treatment level for individual patients.Read moreRead less
Risks And Benefits Of Breast Cancer Screening: BreastScreen WA Cohort Study Of Overdiagnosis And Breast Cancer Mortality
Funder
National Health and Medical Research Council
Funding Amount
$201,524.00
Summary
Overdiagnosis is the major downside of screening for breast cancer. This occurs when screening detects cancers that would not have caused symptoms in the woman's lifetime. This study aims to quantify the amount of overdiagnosis that occurs in the Australian breast cancer screening program (BreastScreen)
TARGETING A NOVEL DNA-DAMAGE SIGNALING PATHWAY TO TREAT GLIOMAS
Funder
National Health and Medical Research Council
Funding Amount
$97,783.00
Summary
Glioblastoma Multiforme (GBM) is a high grade brain tumour for which current treatment modalities are inadequate. Tumour recurrence is almost inevitable and average life expectancy is measured in months. We have identified two proteins as potential therapeutic targets and demonstrated that depleting these proteins in vitro severely impacts on tumour cell viability. We will investigate the impact of targeting these proteins in mouse models of human gliomas and dissect the mechanism that leads to ....Glioblastoma Multiforme (GBM) is a high grade brain tumour for which current treatment modalities are inadequate. Tumour recurrence is almost inevitable and average life expectancy is measured in months. We have identified two proteins as potential therapeutic targets and demonstrated that depleting these proteins in vitro severely impacts on tumour cell viability. We will investigate the impact of targeting these proteins in mouse models of human gliomas and dissect the mechanism that leads to their upregulation in tumour cells.Read moreRead less
Investigating New Molecular Mechanisms That Contribute To The Establishment Of Epigenetic Silencing
Funder
National Health and Medical Research Council
Funding Amount
$1,488,142.00
Summary
Epigenetic marks are changes made to the DNA which help genes to be switched off in some cells and switched on in others e.g. for elastin to be switched on in skin and off in blood. Epigenetic marks are critical to normal development. We are interested in the genes that are necessary to add epigenetic marks to the DNA and understanding how the many genes involved in this process co-operate at the molecular level to switch genes off.